Excerpt from Benign Neonatal ConvulsionsSynonyms, Key Words, and Related Terms: second day seizures, benign neonatal seizures, benign familial neonatal convulsions, benign idiopathic neonatal convulsions, benign familial neonatal seizures, benign idiopathic neonatal seizures, fifth day disease, fifth day fits, BFNC, BINC Please click here to view the full topic text: Benign Neonatal ConvulsionsBackgroundBenign neonatal convulsions are defined as seizures with onset after birth through day 28 in an otherwise healthy child with no other known medical or neurological problems. Such cases may be familial or isolated. Psychomotor development should be normal for a full-term or near full-term infant with benign convulsions. Between seizures, findings on neurologic examination should be normal. Clinically, the seizures are frequent and brief, occasionally occurring many times within a day. The episodes usually resolve within days but may continue for several months and have no neurological sequelae. The occurrence of status epilepticus is common in benign idiopathic neonatal convulsions (BINC) but is uncommon in benign familial neonatal convulsions (BFNC). Because BINC is a diagnosis of exclusion, it is nearly always made in retrospect, when the seizures spontaneously resolve and the infant is found to have neurologically normal development. At the outset, considering how broadly to define benign neonatal convulsions is important: for example, whether to include those with myoclonic or partial onset components or those with a known or treatable etiology. Certainly, multiple presentations of seizures that may have a benign long-term outcome are possible in the neonatal period. Definite advantages exist in approaching the subject from each position. Too broad of a definition in a research situation can lead to confusion when searching for a common pathology. Later, when the mechanisms are more well defined, broader groups not meeting the initial criteria may exist. Clinically, the more important considerations are taking an appropriate approach to the patient and family, making the correct diagnosis, and pursuing treatment options concordant with the situation. Sometimes, the correct clinical plan may include a decision not to treat a benign condition with medications that often are not so benign. It should also be emphasized that a definitive diagnosis may take some time, given the often retrospective nature of the diagnosis. For the purposes of this article, myoclonic and partial onset seizures of the neonatal period are considered separate entities. They are mentioned briefly during the discussion on differential diagnosis. PathophysiologyThe genetics of BFNC is currently an area of active investigation. Inheritance is autosomal dominant. Loci on chromosome arm 20q have been identified for most families. At least one family was identified to have a locus on chromosome arm 8q. Some of these loci have been identified further as specific mutations in the KCNQ2 and KCNQ3 M-type potassium channel proteins. The specific location of the mutation appears to vary from family to family. Several additional genes have been associated with BFNC in single families, including KCNQ5 M-type potassium channel in one family. Another family has been noted to have abnormalities in the acetylcholine alpha-4 receptor subunit, which also has been associated with autosomal dominant nocturnal frontal lobe epilepsy. Expression of the mutated genes in xenopus oocytes has provided some insight into how the potassium channel mutation leads to lowering of the seizure threshold. The potassium current was reduced in the channel expressed by the mutated gene to 5% of that in the channel expressed by the normal gene. However, voltage sensitivity and kinetics were not affected. The effect is therefore to impair repolarization of the neuronal cell membrane, leading to hyperexcitability of the central nervous system. Given the severity of the impairment to the M-type potassium channel, that these seizures are difficult to treat is not surprising, since no currently used antiepileptic medications are known to increase the efficiency of the potassium channel. What is surprising is the self-remitting nature of the condition, that many individuals never have another seizure, and that the profound abnormalities of the voltage-gated potassium channel do not appear to compromise the nervous system in any other way. Possibly, some intrinsic method exists for up-regulating expression of the normal potassium channel genes, or the neurons may find other ways of normalizing the hyperexcitability, but these theories remain to be demonstrated. A number of cases have been reported where BINC or BFNC have preceded the development of epilepsy later in life. Similarly, perhaps, febrile seizures early in life may predispose to later development of epilepsy. Given the polygenic etiology of susceptibility to epilepsy, it is not surprising that an abnormality in part of the system maintaining homeostasis within the neuron should render the neuron more prone to dysfunction. The pathophysiology of BINC has been less well defined and remains somewhat elusive. One issue is that the neonatal brain is more prone to seizures, which has been demonstrated in a number of experimental systems. Several etiologies have been proposed as a result of isolated findings of lowered zinc level in the cerebrospinal fluid and low levels of vitamin B-6. Both of these compounds are important cofactors in ligand-gated ion channel function. However, these findings have not been robust, and the search continues. These seizures likely also are linked in some way to ion channel dysfunction as is found in the familial seizures, but they may be caused by multiple etiologies or occur as a multigenomic entity. These sorts of multifactorial etiologies are more difficult to define precisely. More research is needed in this area, and apparent monogenic diseases, such as BFNC, provide important insight into more complex etiologies. FrequencyUnited StatesBenign neonatal convulsions in the United States are uncommon, ie, not rare but not common, either. Underreporting is likely an issue. Seizures that resolve in the early months of life without sequelae and normal neonatal development are often lost to follow up. Exact frequencies are undetermined. Families identified with the familial form thus far have been primarily of western European origin, although one report from Japan exists. Part of the reason for this is likely the stability of reporting resources in European countries. InternationalBenign neonatal convulsions also are uncommon internationally. Families identified with the familial form thus far have been primarily of western European or Japanese origin. This is certainly an artifact of observation rather than occurrence. Mortality/MorbidityThe risk of seizures later in life is 11-16% in BFNC and somewhat less in BINC, perhaps as low as 2%. Other reported problems have been sporadic and within the incidence range expected for the general population RaceAll cases to date have been reported in families of European origin. SexIn BFNC, the frequency in males is equal to that in females, compatible with simple autosomal dominant inheritance. In BINC, males are affected somewhat more frequently than females (62%) in examined cases (N=199). With such a small number of cases reported, this may be due to reporting bias or simple sampling error, or it may represent a real difference in frequency. Age
Please click here to view the full topic text: Benign Neonatal Convulsions |
| About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|
|||
|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |